文献速递流行病学与生物统计临床试验与 GCP

ABO血型不相容肾移植后的临床结局:系统综述与Meta分析

Clinical outcomes after ABO-incompatible renal transplantation: a systematic review and meta-analysis.
PubMed 文献 · Lancet · 2019-04-18

该系统综述与Meta分析纳入截至2017年12月31日发表的40项观察性研究、49个患者组、共65063例患者,其中7098例接受ABO血型不相容肾移植(ABOi-rTx)。与ABO血型相容肾移植(ABOc-rTx)相比,ABOi-rTx与移植后1年、3年、5年全因死亡率显著升高相关,1年和3年死亡删失移植肾存活率更低,5年后移植肾丢失及8年后患者生存与ABOc-rTx相当。

要点

  • ABOi-rTx与ABOc-rTx相比,移植后1年、3年、5年全因死亡风险显著升高。
  • ABOi-rTx的死亡删失移植肾存活率在1年和3年时低于ABOc-rTx。
  • 5年后移植肾丢失和8年后患者生存与ABOc-rTx相当。

核心结论

  • 尽管脱敏方案和ABOi-rTx手术流程已有进步,与ABOc-rTx相比,移植后前3年内仍发现超额死亡和移植肾丢失。
  • 仅5年后的长期结局在生存率和器官功能方面达到等效。
  • 对感染、器官排斥和出血风险增加的认识可改善患者照护,并促进配对肾脏交换计划的努力。

研究设计与样本

  • 系统综述与Meta分析,检索Cochrane Central Register of Controlled Trials(CENTRAL)、Embase Ovid、MEDLINE Ovid和PubMed中截至2017年12月31日发表的观察性研究。
  • 纳入标准为报告ABOi-rTx后结局数据(随访≥1年)并包含ABO血型相容对照组的试验。
  • 排除病例报告、社论、综述、信件、动物研究、会议论文、无法提取数据的研究、非肾实体器官和骨髓移植研究以及 deceased donor ABOc-rTx。
  • 共筛查1264项研究,纳入40项研究、49个患者组,65063例患者符合分析条件,其中7098例接受ABOi-rTx。
  • 主要终点为移植后1年、3年、5年和超过8年的全因死亡率和移植肾存活率;I2=0时采用固定效应模型,I2>0时同时采用固定效应和随机效应模型。

主要发现

  • 与ABOc-rTx相比,ABOi-rTx与移植后1年死亡率显著更高相关(OR 2.17,95%CI 1.63-2.90,p<0.0001;I2=37%)。
  • ABOi-rTx与移植后3年死亡率显著更高相关(OR 1.89,95%CI 1.46-2.45,p<0.0001;I2=29%)。
  • ABOi-rTx与移植后5年死亡率显著更高相关(OR 1.47,95%CI 1.08-2.00,p=0.010;I2=68%)。
  • 死亡删失移植肾存活率在ABOi-rTx中低于ABOc-rTx,仅见于1年(OR 2.52,95%CI 1.80-3.54,p<0.0001;I2=61%)和3年(OR 1.59,95%CI 1.15-2.18,p=0.0040;I2=58%)。
  • 5年后移植肾丢失与ABOc-rTx相当,8年后患者生存与ABOc-rTx相当;未检测到发表偏倚,结果在移植后5年内对试验序贯分析稳健,此后数据变得无效或不确定。

关键数值与推荐

  • ABOi-rTx与ABOc-rTx相比,1年全因死亡率OR 2.17(95%CI 1.63-2.90,p<0.0001;I2=37%)。
  • ABOi-rTx与ABOc-rTx相比,3年全因死亡率OR 1.89(95%CI 1.46-2.45,p<0.0001;I2=29%)。
  • ABOi-rTx与ABOc-rTx相比,5年全因死亡率OR 1.47(95%CI 1.08-2.00,p=0.010;I2=68%)。
  • ABOi-rTx与ABOc-rTx相比,1年死亡删失移植肾存活OR 2.52(95%CI 1.80-3.54,p<0.0001;I2=61%)。
  • ABOi-rTx与ABOc-rTx相比,3年死亡删失移植肾存活OR 1.59(95%CI 1.15-2.18,p=0.0040;I2=58%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 5年后数据变得无效或不确定。
  • 5年死亡率分析异质性I2=68%,1年死亡删失移植肾存活分析异质性I2=61%,3年死亡删失移植肾存活分析异质性I2=58%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ABO-incompatible renal transplantation (ABOi-rTx) is increasingly used to overcome organ shortage. Evidence about its non-inferiority in comparison with ABO-compatible renal transplantation (ABOc-rTx) needs to be analysed at early and late timepoints. We aimed to investigate differences in outcome after ABOi-rTX and ABOc-rTX. METHODS: We did a systematic review and meta-analysis of observational studies published up until Dec 31, 2017, that reported outcome data (≥1 year of follow-up) after ABOi-rTx and included an ABO-compatible control group, by searching the Cochrane Central Register of Controlled Trials (CENTRAL), Embase Ovid, MEDLINE Ovid, and PubMed. Trials on recipients of ABOi-rTx were assessed, if an ABO-compatible control group was included and if outcome data on at least graft or recipient survival with 1 year or more of follow-up were available. Exclusion criteria included case reports, editorials, reviews and letters, animal studies, meeting papers, studies unable to extract data, non-renal solid organ and bone-marrow transplant studies, and deceased donor ABOc-rTx. Data were extracted from published reports. Primary endpoints were all-cause mortality and graft survival at 1, 3, 5, and more than 8 years after transplantation. In the meta-analysis, we used a fixed-effects model if the I2 value was 0, and both a fixed-effects and random-effects model if I2 was more than 0. This study is registered with PROSPERO, number CRD42018094550. FINDINGS: 1264 studies were screened and 40 studies including 49 patient groups were identified. 65 063 patients were eligible for analysis, 7098 of whom had undergone ABOi-rTx. Compared with ABOc-rTx, ABOi-rTx was associated with significantly higher 1-year mortality (odds ratio [OR] 2·17 [95% CI 1·63-2·90], p<0·0001; I2=37%), 3 years (OR 1·89 [1·46-2·45], p<0·0001; I2=29%), and 5 years (OR 1·47 [1·08-2·00], p=0·010; I2=68%) following transplantation. Death-censored graft survival was lower with ABOi-rTx than with ABOc-rTx at 1 year (OR 2·52 [1·80-3·54], p<0·0001; I2=61%) and 3 years (OR 1·59 [1·15-2·18], p=0·0040; I2=58%) only. Graft losses were equivalent to that of ABOc-rTx after 5 years and patient survival after 8 years. No publication bias was detected and the results were robust to trial sequential analysis until 5 years after transplantation; thereafter, data became futile or inconclusive. INTERPRETATION: Despite progress in desensitisation protocols and optimisation of ABOi-rTx procedures, excess mortality and loss of kidney grafts was found compared with ABOc-rTx within the first 3 years after transplantation. Only long-term outcomes after 5 years yielded equivalent survival rates and organ function. Awareness of the increased risks of infection, organ rejection, and bleeding could improve care of patients and promote efforts towards paired kidney exchange programmes. FUNDING: None.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Scurt FG, Ewert L, Mertens PR, et al. Clinical outcomes after ABO-incompatible renal transplantation: a systematic review and meta-analysis. Lancet. 2019. PMID: 31006573. doi:10.1016/S0140-6736(18)32091-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。